American Capital Advisory’s Charles River Laboratories CRL Stock Holding History

American Capital Advisory’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454	Hold	2	–	–	﹤0.01%	971
2026 Q1	$345	Buy	+2	New	+$371	﹤0.01%	936
2025 Q2	–	Sell	-1	Closed	-$151	–	894
2025 Q1	$151	Buy	+1	New	+$168	﹤0.01%	768

Other funds holding CRL

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

LKIM

Lawson Kroeker Investment Management Omaha, Nebraska $361M AUM 22.26% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

American Capital Advisory's CRL Position: Q2 2026 in Review

American Capital Advisory held its Charles River Laboratories (CRL) position steady in Q2 2026 at 2 shares worth $454. The position accounts for ﹤0.01% of the portfolio, ranked #971.

American Capital Advisory first reported a position in CRL in Q1 2025 and has held it in 3 quarters since. 150 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

American Capital Advisory held 2 shares of Charles River Laboratories worth $454 as of Q2 2026.
American Capital Advisory left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #971 holding.
American Capital Advisory first reported a position in Charles River Laboratories in Q1 2025 and has held it in 3 quarters since.
150 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.